Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized local steroid therapy after surgery for eosinophilic chronic rhinosinusitis involving the frontal sinus
ChiCTR2200056957Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of budesonide in eosinophilic chronic rhinosinusitis (ECRS) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Visual Analogue Scale of Nasal Symptoms, Lund-Kennedy Endoscopy Score and 1 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
eosinophilic chronic rhinosinusitis (ECRS)
Beyond the preview
Go deeper on ChiCTR2200056957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056957.